A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma - Trial NCT06371157
Access comprehensive clinical trial information for NCT06371157 through Pure Global AI's free database. This Phase 3 trial is sponsored by Akeso and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 469 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Akeso
Timeline & Enrollment
Phase 3
Jul 02, 2024
May 23, 2026
Primary Outcome
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Summary
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial
 chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic
 hepatocellular carcinoma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06371157
Non-Device Trial